Hematopoietic Cell Transplantation for Diffuse Large B-Cell and Follicular Lymphoma: Current Controversies and Advances
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Narendranath Epperla, Mehdi Hamadani Non-Hodgkin’s lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with diverse biologic, histologic, and clinical features. With a better understanding of the molecular pathogenesis, recently there have been major advances in the treatment of NHLs including addition of novel monoclonal antibodies, targeted therapies, and immune activators to the therapy armamentarium. Despite these remarkable developments, autologous hematopoietic cell transplantation (...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Complications of Hematopoietic Stem Transplantation: Fungal Infections
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at increased risk of invasive fungal infections, especially during the early neutropenic phase and severe graft-versus-host disease. Mold-active prophylaxis should be limited to the highest risk groups. Empiric antifungal therapy for HSCT with persistent febrile neutropenia is associated with unacceptable response rates, unnecessary antifungal therapy, increased risk of toxicity, and inflated costs. Em...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Memory T Cells: A Helpful Guard for Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-versus-Host Disease
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Wei Huang, Nelson J. Chao Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (AHSCT) and the major cause of nonrelapse morbidity and mortality of AHSCT. In AHSCT, donor T cells facilitate hematopoietic stem cell (HSC) engraftment, contribute to anti-infection immunity, and mediate graft-versus-leukemia (GVL) responses. However, activated alloreactive T cells also attack recipient cells in vital organs, leading to GVHD. Different T-cell subsets, including na...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Myasthenia Gravis after Allogeneic Bone Marrow Transplantation: A Case Report and Literature Review
Publication date: Available online 18 May 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Yutaka Tsutsumi, Takashi Kamiishi, Ryo Kikuchi, Shinichi Ito, Satomi Matsuoka, Takanori Teshima A 52-year-old man with acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation and developed extensive chronic graft-versus-host disease and myasthenia gravis (MG), which became involved with oculobulbar and proximal upper and lower limb weakness in 677 days. In the literature, we identified 24 cases where MG developed after allo-SCT. Graft-versus-host disease development and male recipients of ...
Source: Hematology Oncology and Stem Cell Therapy - May 19, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Publication date: Available online 19 May 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Hind Rafei, Mohamed A. Kharfan-Dabaja More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibitor of BC...
Source: Hematology Oncology and Stem Cell Therapy - May 19, 2017 Category: Cancer & Oncology Source Type: research

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.
Conclusion Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 26, 2017 Category: Cancer & Oncology Source Type: research

Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Bushra Salman, Mohammed Al-Za'abi, Mohammed Al-Huneini, David Dennison, Abdulhakeem Al-Rawas, Salam Al-Kindi, Khalil Al-Farsi, Melanie Tauro, Murtadha Al-Khabori Busulfan (Bu)-based preparative regimens in hematopoietic stem cell transplantation are commonly used. Previous studies have shown that Bu at a fixed dose of 3.2mg/kg/day (FBD) given intravenously decreases variability in drug pharmacokinetics and this decreases the dependency on therapeutic drug monitoring (TDM) of Bu. We compared the Bu dose given using T...
Source: Hematology Oncology and Stem Cell Therapy - April 25, 2017 Category: Cancer & Oncology Source Type: research

Mantle cell lymphoma: Contemporary diagnostic and treatment perspectives in the age of personalized medicine
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Jose Sandoval-Sus, Eduardo M. Sotomayor, Bijal D. Shah Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and deintensified approaches. In the following review we provide a therapeutic roadmap to strategically guide treatment for newly diagnosed and relapsed/refractory patients highlighting pi...
Source: Hematology Oncology and Stem Cell Therapy - April 11, 2017 Category: Cancer & Oncology Source Type: research

Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali H. Algiraigri, Nicola A.M. Wright, Elizabeth Oddone Paolucci, Aliya Kassam Nontransfusion-dependent β-thalassemia (NTDβT) syndromes consist of β-thalassemia intermedia and moderate hemoglobin E/β thalassemias. They are characterized by varying degrees of chronic anemia and a wide spectrum of complications due to ineffective erythropoiesis and iron overload from chronic transfusions. Hydroxyurea (HU), an oral chemotherapeutic drug, is anticipated to decrease disease severity. We performed a me...
Source: Hematology Oncology and Stem Cell Therapy - April 11, 2017 Category: Cancer & Oncology Source Type: research

Busulfan drug monitoring is needed in patients undergoing allogeneic stem cell transplantation
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Bushra Salman, Mohammed Al-Zaabi, Mohammed Al-Huneini, David Dennison, Abdulhakeem Al-Rawas, Salam Al-Kindi, Khalil Al-Farsi, Melanie Tauro, Murtadha Al-Khabori Busulfan (Bu)-based preparative regimens in hematopoietic stem cell transplantation are commonly used. Previous studies have shown that Bu at a fixed dose of 3.2mg/kg/day (FBD) given intravenously decreases variability in drug pharmacokinetics and this decreases the dependency on therapeutic drug monitoring (TDM) of Bu. We compared the Bu dose given using TD...
Source: Hematology Oncology and Stem Cell Therapy - April 11, 2017 Category: Cancer & Oncology Source Type: research

Fever After Peripheral Blood Stem Cell Infusion in Haploidentical Transplantation with Post-transplant Cyclophosphamide
Conclusion Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 4, 2017 Category: Cancer & Oncology Source Type: research

The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases
Publication date: Available online 31 March 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Meenu Angi, Vandana Kamath, S. Yuvarani, J. Meena, Usha Sitaram, Marie Therese Manipadam, Sukesh Nair, Abhijeet Ganapule, N.A. Fouzia, Aby Abraham, Auro Viswabandya, B. Poonkuzhali, Biju George, Vikram Mathews, Alok Srivastava, Vivi M. Srivastava (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 1, 2017 Category: Cancer & Oncology Source Type: research

Waldenstr öm’s macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated cancer antigen 125
Publication date: Available online 31 March 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Patrick Eulitt, Denise Fabian, Crystal Kelly, Jessica Hemminger, Basem M. William (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - March 31, 2017 Category: Cancer & Oncology Source Type: research

CXCR4 (CD184) Expression on Stem cell Harvest and CD34+ Cells Post-transplant
Conclusion SDF-1/CXCR4 axis plays a crucial role in engraftment; however, more studies are warranted to assess their expression post-transplant. Evaluating the ligand (chemokine, SDF-1) or its receptor (CXCR4) may serve as potential surrogate markers for assessment of engraftment. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - March 1, 2017 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature
We report a case of myelodysplastic syndrome progressing to AML with calreticulin driver mutation in an adult male with TAR syndrome who was successfully treated with hematopoietic allogeneic stem cell transplantation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 24, 2017 Category: Cancer & Oncology Source Type: research

A case of T-cell lymphoproliferative disorder associated with hypereosinophilia with excellent response to mycophenolate mofetil
We report a case of T-cell lymphoproliferation associated with hypereosinophilia, which has been successfully treated with mycophenolate mofetil, with resolution of skin lesions and normalization of eosinophil count and immunoglobulin E level. We believe this is a clinically relevant case since this is a rare disease with little known knowledge on its best treatment modality. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 5, 2017 Category: Cancer & Oncology Source Type: research

Glomangiopericytoma (Hemangiopericytoma) of the Maxillary Sinus and Sinonasal Tract
Publication date: Available online 1 February 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Samaher Al Saad, Razan Al Hadlaq, Nabil Al-Zaher Glomangiopericytoma of the sinonasal tract (formerly known as hemangiopericytoma) is a rare soft tissue tumor with a perivascular myoid phenotype. It accounts for 1 percent of all vascular tumors. Herein, it is our pleasure to report that in 2006, we, Head & Neck Surgeons at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia, had the opportunity to contribute to the curative management of a 22-year-old patient, a registered nu...
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Relapse of Hodgkin Lymphoma after Autologous Transplantation: Time to Rethink Treatment?
Publication date: Available online 1 February 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Yogesh Jethava, Guru Subramanian Guru Murthy, Mehdi Hamadani Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation (autologous HCT) is a major therapeutic challenge. Its management, at least in younger patients, traditionally involves salvage chemotherapy aiming to achieve disease remission followed by consolidation with allogeneic hematopoietic cell transplantation (allogeneic HCT) in eligible patients. The efficacy of salvage therapy is variable and newer combination chemotherapy regim...
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Study of CD4+, CD8+, and Natural Killer Cells (CD16+, CD56+) in Children with Immune Thrombocytopenic Purpura
Conclusion ITP is associated with immunity dysfunction denoted by the increase in cytotoxic T lymphocytes and the decrease in natural killer cells. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Diagnosis of Variant RARA Translocation Using Standard Dual-Color Dual-Fusion PML/RARA FISH probes: An Illustrative Report
Publication date: Available online 1 February 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Manish K. Singh, Mayur Parihar, Neeraj Arora, D.K. Mishra, Saurabh J. Bhave, Mammen Chandy Acute promyelocytic leukemia (APML) with variant RARa translocations comprises 1–2% of APML cases. However, the diagnosis of these cases is challenging as the routine practice includes fluorescence in situ hybridization (FISH) reverse transcription polymerase chain reaction targeting the PML and RARA genes to detect PML/RARA fusions. Here, we report a case highlighting the importance of atypical FISH signal patterns i...
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Synovial Sarcoma of the Hard Palate: The Third Case in the Medical Literature
Publication date: Available online 1 February 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Aseel Doubi, Motaz Doubi, Nabil Al Zaher, Asma Tulbah (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

A Case of T-cell Lymphoprliferative Disorder Associated with Hypereosinophilia with Excellent Response to Mycophenolate Mofetil
We report a case of T-cell lymphoproliferation associated with hypereosinophilia, which has been successfully treated with mycophenolate mofetil, with resolution of skin lesions and normalization of eosinophil count and immunoglobulin E level. We believe this is a clinically relevant case since this is a rare disease with little known knowledge on its best treatment modality. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Prognosis Biomarkers Evaluation in Chronic Lymphocytic Leukemia
Conclusion ZAP-70 gene expression was not detected as a discriminant biomarker in these CLL patients. An imbalance between apoptosis-related proteins was observed in the present study, corroborating the hypothesis of increased survival of lymphocytes in CLL patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 1, 2017 Category: Cancer & Oncology Source Type: research

Prevalence and Relative Proportions of CLL and non-CLL Monoclonal B-cell Lymphocytosis Phenotypes in the Middle Eastern Population
Publication date: Available online 9 November 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mahmoud Aljurf, Faisal Rawas, Randa Alnounou, Nasir Bakshi, Naeem Chaudhri, Salem Khalil, Fahad Almohareb, Maher Albitar Chronic lymphocytic leukemia (CLL) is considered more common in Western countries and its incidence is believed to decrease moving east across the globe .Therefore, the prevalence of monoclonal B-cell lymphocytosis (MBL), a pre-CLL condition, is also expected to be less common in non-Western countries. Monoclonal B-cell lymphocytosis1 is characterized by the presence of less than 5000 x 109/L c...
Source: Hematology Oncology and Stem Cell Therapy - November 9, 2016 Category: Cancer & Oncology Source Type: research

Vesicoileal fistula and Clostridium difficile colitis in a child with acute lymphoblastic leukemia
We report a rare case of a child with acute lymphoblastic leukemia and vesicoileal fistula. The patient presented 3 weeks after finishing chemotherapy with urinary tract infection symptoms, fecaluria, and hyperchloremic metabolic acidosis. The patient was found to have Clostridium difficile colitis and a vesicoileal fistula with no leukemic infiltration of the involved intestines or the urinary bladder. Although multiple types of fistulas are reported in immunocompromised patients, no such case has been reported in published literature. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - November 9, 2016 Category: Cancer & Oncology Source Type: research

A Novel TNFRSF1A Gene Mutation in a Patient with Tumor Necrosis Factor Receptor-associated Periodic Syndrome
Publication date: Available online 19 October 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Alireza Khabazi, Mahafarin Maralani, Sasan Andalib, Ebrahim Sakhinia Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a periodic fever syndrome inherited in an autosomal dominant fashion. It stems from mutations in the TNFRSF1A gene that expresses the receptor for tumor necrosis factor α. A patient with TRAPS may present with prolonged episodes of fever attacks, abdominal pain, severe myalgia, and painful erythema on the trunk or extremities. Here, we report the case of an 8-year-old b...
Source: Hematology Oncology and Stem Cell Therapy - October 24, 2016 Category: Cancer & Oncology Source Type: research

Diagnostic Value of Sepsis Biomarkers in Hematopoietic Stem Cell Transplant Recipients in a Condition of High Prevalence of Gram-negative Pathogens
Conclusion] Presepsin may be recommended in adult patients with suspected gram-negative BSI after HSCT as a possible additional supplementary test with a cut-off value of 218 pg/mL. PCT is inferior to presepsin in terms of sensitivity and specificity, but still shows a good quality of diagnostic value with an optimal cut-off value of 1.5 ng/mL. CRP showed an average diagnostic value with low sensitivity (40%) and should not be routinely recommended as a biomarker in adult patients with suspected BSI after HSCT in a condition of high prevalence of gram-negative pathogens. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 24, 2016 Category: Cancer & Oncology Source Type: research

Central Nervous System Infection Following Allogeneic Hematopoietic Stem Cell Transplantation
Conclusion Multivariate analysis revealed that high-risk disease status was a risk factor for developing CNS infection (p = .02), and that overall survival at 3 years after allo-HSCT was 33% in patients with CNS infection and 53% in those without CNS infection (p = .04). (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 18, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review
Conclusion According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 3, 2016 Category: Cancer & Oncology Source Type: research

Acute Promyelocytic Leukemia with Increased Bone Marrow Reticulin Fibrosis: Description of Three Cases and Review of the Literature
Publication date: Available online 2 September 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Iman Abou Dalle, Samer Nassif, Ali Bazarbachi Pathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts. Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia wi...
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

MYH9-Related Disorder, a Probable May –Hegglin Anomaly Case Series: A Tertiary Care Experience
Conclusion A diagnosis of MHA could be made based on a thorough peripheral blood smear examination, which also helps to avoid a misdiagnosis of immune thrombocytopenia. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer
Conclusions Adding cetuximab to pre-operative concurrent capecitabine and radiotherapy provides modest efficacy with manageable toxicity (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

Yield of Computed Tomography Pulmonary Angiogram in the Emergency Department in Cancer Patients Suspected to have Pulmonary Embolism
Conclusion The yield of CTPA to rule out PE in patients with cancer presenting in the ED is low. Following a validated decision-making protocol such as Wells criteria may significantly decrease the number of CTPA used in the ED. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

Polycythemia Vera Masked Due to Severe Iron Deficiency Anemia
We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed with polycythemia vera. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

The JAK2 V617F Mutation and Thrombocytopenia
Publication date: Available online 2 September 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Stephen E. Langabeer, Karl Haslam (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - September 2, 2016 Category: Cancer & Oncology Source Type: research

Impact of conditioning and engraftment on iron status in hematopoietic stem cell transplantation: Contribution of labile plasma iron
Publication date: Available online 6 August 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Flávio Augusto Naoum, Breno Pannia Espósito, Rodolfo Delfini Cançado (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 8, 2016 Category: Cancer & Oncology Source Type: research

The Effects of Hematopoietic Stem Cell Transplant on Splenic Extramedullary Hematopoiesis in Patients with Myeloproliferative Neoplasm-associated Myelofibrosis
Conclusion HSCT reduces/abrogates splenic EMH and is associated with an increased number of Gamna–Gandy bodies, which may suggest vascular damage. The lack of stromal changes in spleens removed shortly after transplant is in line with similar observations in the BM, where a longer interval is often necessary for resolution of fibrosis. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 6, 2016 Category: Cancer & Oncology Source Type: research

The Impact of Conditioning and Engraftment on Iron Status in Hematopoietic Stem Cell Transplantation: The Contribution of Labile Plasma Iron
Publication date: Available online 6 August 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Flávio Augusto Naoum, Breno Pannia Espósito, Rodolfo Delfini Cançado (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 6, 2016 Category: Cancer & Oncology Source Type: research

Severe Plasmodium vivax Cerebral Malaria Complicated by Hemophagocytic Lymphohistiocytosis Treated with Artesunate and Doxycycline
Publication date: Available online 6 August 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sawsan Amireh, Hamid Shaaban, Gunwant Guron Malaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflammatory disease entity which can be challenging to diagnose and treat. It is usually associated with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax. Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diagnosed as having c...
Source: Hematology Oncology and Stem Cell Therapy - August 6, 2016 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011 –2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT)
Conclusion There is a discernable increase of HSCT rate in the EMRO region with a significant expansion in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However, further research of outcome data and the development of regional donor banks (cord blood and matched unrelated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collaboration within the EMBMT and globally. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2016 Category: Cancer & Oncology Source Type: research

Characterization of a novel variant BCR –ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring
Publication date: Available online 17 March 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mireille Crampe, Karl Haslam, Johanna Kelly, Eibhlin Conneally, Stephen E. Langabeer Molecular monitoring of BCR–ABL1 transcript levels using quantitative polymerase chain reaction is an essential part of the modern management of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Establishing the diagnostic BCR–ABL1 fusion transcript is necessary in order to select appropriate primers and probes for such monitoring. A case is described in which quantitative polymerase chain...
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2016 Category: Cancer & Oncology Source Type: research

Chediak –Higashi syndrome presenting in accelerated phase: A case report and literature review
Publication date: June 2016 Source:Hematology/Oncology and Stem Cell Therapy, Volume 9, Issue 2 Author(s): I. Maaloul, J. Talmoudi, I. Chabchoub, L. Ayadi, T.H. Kamoun, T. Boudawara, C.H. Kallel, M. Hachicha Chediak–Higashi syndrome (CHS) is a rare autosomal recessive lysosomal disorder characterized by frequent infections, oculocutaneous albinism, bleeding diathesis, and progressive neurologic deterioration. In 85% of cases, CHS patients develop the accelerated phase characterized by pancytopenia, high fever, and lymphohistiocytic infiltration of liver, spleen, and lymph nodes. Treatment of accelerated-pha...
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2016 Category: Cancer & Oncology Source Type: research

Paraneoplastic pemphigus as a presentation of acute myeloid leukemia: Early diagnosis and remission
We describe a previously unreported case of PNP associated with acute myeloid leukemia (AML) where the patient presented with a nonhealing ulcer and hemorrhagic crusting on the face that did not respond to antimicrobials and steroids. Investigations revealed leukocytosis with peripherally circulating blasts. Skin biopsy revealed an evolving PNP and bone marrow biopsy confirmed evidence of AML. The patient underwent induction, consolidation, and then successful allogenic bone marrow transplantation with complete remission. The skin lesion, which was initially refractory to treatments, surprisingly resolved within 7days of s...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Detection of t(8;14) C-MYC/IGH gene rearrangement by long-distance polymerase chain reaction in patients with diffuse large B-cell lymphoma
Conclusion LD-PCR can be used for the detection of t(8;14) C-MYC/IGH gene rearrangement in patients with DLBCL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
Conclusion Obinutuzumab has an established safety profile in patients with CLL, but our case is the first reported case of a paraneoplastic, immune complex-mediated MPGN in CLL being treated with obinutuzumab. Obinutuzumab should be explored as a potential option in patients with CLL and MPGN. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion
Publication date: Available online 23 June 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mireille Crampe, Jennifer Garry, Stephen E. Langabeer, Philip T. Murphy (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

CALR mutation profile in Irish patients with myeloproliferative neoplasms
Publication date: Available online 23 June 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Karl Haslam, Eibhlin Conneally, Catherine M. Flynn, Mary R. Cahill, Oonagh Gilligan, Derville O’Shea, Stephen E. Langabeer Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incid...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia
Publication date: Available online 23 June 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ahmad Alhuraiji, Nitin Jain (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient
Publication date: Available online 23 June 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ernesto Ayala, Denise LaFave, Taiga Nishihori, Mohamed A. Kharfan-Dabaja Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe and often overwhelming systemic hyper-inflammatory syndrome generally presenting with unexplained fevers, hepatosplenomegaly, and progressive multi-organ dysfunction. Treatment of HLH has two major goals: Halting the triggering event and controlling the overactive immune system. However, patients with primary or recurrent secondary HLH should subsequently undergo allogeneic HCT ...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2016 Category: Cancer & Oncology Source Type: research

Integrating Mutation Variant Allele Frequency into Clinical Practice in Myeloid Malignancies
Publication date: Available online 11 May 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): David A. Sallman, Eric Padron Hematologic myeloid neoplasms represent a heterogeneous group of disorders with defined clinical and pathologic characteristics. However, intensive investigation into the genetic abnormalities of these diseases has not only significantly advanced our understanding, but also revolutionized our diagnostic and prognostic capabilities. Moreover, more recent discovery on the impact of clonal burden has highlighted the critical and dynamic role of clonal evolution over time, which is integr...
Source: Hematology Oncology and Stem Cell Therapy - May 11, 2016 Category: Cancer & Oncology Source Type: research